Search

CN-121985931-A - Rhamnolipids for scalp health

CN121985931ACN 121985931 ACN121985931 ACN 121985931ACN-121985931-A

Abstract

The technology presented herein relates generally to the formulation of dandruff treatment compositions and to the formulation and use of rhamnolipids in these compositions. More particularly, the present technology relates to compositions and methods for controlling, treating, or preventing dandruff in subjects suffering from or susceptible to dandruff. The present technology also relates to compositions and methods for treating excess malassezia species on mammalian skin.

Inventors

  • A. Nikolov
  • C. Baghiracharia
  • K. Straut

Assignees

  • 斯蒂潘公司

Dates

Publication Date
20260505
Application Date
20240926
Priority Date
20230927

Claims (20)

  1. 1. A composition for treating dandruff, the composition comprising: (a) A mixture of rhamnolipid salts in an amount of about 0.01 to about 30 wt% based on the total weight of the composition, wherein the mixture of rhamnolipid salts comprises mono-and di-rhamnolipids in a weight ratio of 10:90 to 90:10 mono-rhamnolipids to di-rhamnolipids based on the total weight of the mixture of rhamnolipid salts, rha-C10 mono-rhamnolipid salts in an amount of about 5 to about 50 wt% based on the total weight of the mixture of rhamnolipid salts, and RhaRha to about 80 wt% of RhaRha-C10 di-rhamnolipid salts based on the total weight of the mixture of rhamnolipid salts; (b) At least one surfactant selected from the group consisting of anionic surfactants, amphoteric surfactants, nonionic surfactants, cationic surfactants, and combinations thereof, and (C) A dermatologically acceptable carrier in an amount up to a total of 100% by weight, Wherein the composition reduces the presence of malassezia species on mammalian skin in the absence of other antifungal actives.
  2. 2. A composition for treating dandruff, the composition comprising: (a) A mixture of zinc-rhamnolipid salts in an amount of from about 0.01 to about 30 wt% based on the total weight of the composition, wherein the mixture of rhamnolipid salts comprises mono-and di-rhamnolipids in a weight ratio of from 10:90 to 90:10 mono-rhamnolipids to di-rhamnolipids based on the total weight of the mixture of rhamnolipid salts, rha-C10 mono-rhamnolipid salts in an amount of from about 5 to about 50 wt% based on the total weight of the mixture of rhamnolipid salts, and RhaRha-C10 di-rhamnolipid salts in an amount of from about 30 to about 80 wt% based on the total weight of the mixture of rhamnolipid salts, and (B) A dermatologically acceptable carrier in an amount up to a total of 100% by weight, (C) Wherein the composition reduces malassezia species present on mammalian skin.
  3. 3. The composition of claim 2, wherein the composition further comprises at least one surfactant selected from the group consisting of anionic surfactants, amphoteric surfactants, nonionic surfactants, cationic surfactants, and combinations thereof.
  4. 4. The composition of any one of claims 1 to 3, wherein the amount of rhamnolipid salt is from about 0.1wt% to about 10 wt%, from 0.1wt% to about 5 wt%, from about 0.3 wt% to about 3 wt%, from about 0.3 wt% to about 2 wt%, or from about 0.3 wt% to about 1wt% of the composition.
  5. 5. The composition of claims 1 or 3-4, wherein the at least one surfactant is present in an amount of about 2% to about 40% by weight of the composition.
  6. 6. The composition of any one of claims 1 or 3 to 5, wherein the at least one surfactant comprises an anionic surfactant in an amount of from about 1% to about 40% by weight of the composition.
  7. 7. The composition of any one of claims 1 or 3-6, wherein the at least one surfactant comprises an amphoteric surfactant in an amount of about 1% to about 40% by weight of the composition, about 1% to about 30% by weight of the composition, about 1% to about 20% by weight of the composition, or about 1% to about 10% by weight of the composition.
  8. 8. The composition of any one of claims 1 to 7 wherein the mixture of rhamnolipid salts comprises mono-and di-rhamnolipids in a weight ratio of 40:60 to 60:40 mono-rhamnolipid to di-rhamnolipid, 45:55 to 55:45 mono-rhamnolipid to di-rhamnolipid, or 47:53 to 53:47 mono-rhamnolipid to di-rhamnolipid, based on the total weight of the mixture of rhamnolipid salts.
  9. 9. The composition of any one of claims 1 to 8, wherein the mixture of rhamnolipid salts comprises from about 20 wt% to about 60 wt%, from about 30 wt% to about 50 wt%, from about 40 wt% to about 50 wt%, or from about 45 wt% to about 48 wt% of mono rhamnolipid, based on the total weight of the mixture of rhamnolipid salts.
  10. 10. The composition of any one of claims 1 to 9, wherein the mixture of rhamnolipid salts comprises from about 20 wt% to about 70 wt%, from about 30 wt% to about 60 wt%, from about 40 wt% to about 60 wt%, from about 45 wt% to about 55 wt%, or from about 50 wt% to about 55 wt% of a ditrhamnolipid, based on the total weight of the mixture of rhamnolipid salts.
  11. 11. The composition of any one of claims 1 to 10, wherein the mixture of rhamnolipid salts comprises Rha-C10 mono rhamnolipid salts in an amount of from about 20 wt% to about 50 wt%, from about 25 wt% to about 45 wt%, from about 30 wt% to about 40 wt%, or from about 35 wt% to about 38 wt%, based on the total weight of the mixture of rhamnolipid salts.
  12. 12. The composition of any one of claims 1 to 11, wherein the mixture of rhamnolipid salts comprises RhaRha-C10 di rhamnolipid salts in an amount of from about 20 wt% to about 50 wt%, from about 25 wt% to about 45 wt%, from about 30 wt% to about 40 wt%, or from about 35 wt% to about 38 wt%, based on the total weight of the mixture of rhamnolipid salts.
  13. 13. The composition of any one of claims 1 to 12, wherein the mixture of rhamnolipid salts comprises Rha-C8-C10 mono rhamnolipid salts in an amount of from about 1 wt% to about 10 wt%, from about 1 wt% to about 5wt%, from about 2 wt% to about 5wt%, or from about 3 wt% to about 4 wt%, based on the total weight of the mixture of rhamnolipid salts.
  14. 14. The composition of any one of claims 1 to 13, wherein the mixture of rhamnolipid salts comprises RhaRha-C8-C10 di-rhamnolipid salts in an amount of from about 1 wt% to about 10 wt%, from about 1 wt% to about 5 wt%, from about 2 wt% to about 5 wt%, or from about 3 wt% to about 4 wt%, based on the total weight of the mixture of rhamnolipid salts.
  15. 15. The composition of any one of claims 1 to 14, wherein the mixture of rhamnolipid salts comprises Rha-C10-C12 mono rhamnolipid salt in an amount of from about 1wt% to about 10 wt%, from about 1wt% to about 5wt%, from about 2 wt% to about 5wt%, from about 3 wt% to about 5wt%, or from about 4 wt% to about 5wt%, based on the total weight of the mixture of rhamnolipid salts.
  16. 16. The composition of any one of claims 1to 15, wherein the mixture of rhamnolipid salts comprises RhaRha-C10-C12 di-rhamnolipid salts in an amount of from about 1 wt% to about 20 wt%, from about 5 wt% to about 15 wt%, from about 10 wt% to about 15 wt%, or from about 10 wt% to about 12 wt%, based on the total weight of the mixture of rhamnolipid salts.
  17. 17. The composition of any one of claims 1 to 16, wherein the composition comprises one or more additives.
  18. 18. The composition of claim 17, wherein the one or more additives comprise one or more of a pH adjuster, a skin conditioner, an antioxidant, a preservative, a fragrance, a pigment, and a dye.
  19. 19. The composition of claim 17, wherein the one or more additives comprise a monoglyceride, a diglyceride, or a combination thereof.
  20. 20. The composition of any of claims 1 or 3 to 19, wherein the at least one surfactant is selected from the group consisting of sulfonated alkylbenzenes, sulfonated methyl esters, sulfonated alpha olefins, alkane sulfonates, alkyl sulfates, alkyl alkoxy carbonates, alkyl sulfonates, alkyl alkoxy sulfonates, acyl lactylates, alkyl isethionates, alkyl sarcosinates, alkyl betaines, alkyl amidopropyl betaines, alkyl sulfobetaines, alkyl amine oxides, quaternary ammonium compounds, salts thereof, and combinations thereof.

Description

Rhamnolipids for scalp health Technical Field The present technology relates generally to the use of rhamnolipids for improving and/or promoting the maintenance of healthy scalp. More particularly, the present technology relates to compositions and methods for treating and/or preventing dandruff circulation by applying a composition comprising a mixture of specific rhamnolipids to human scalp. In certain embodiments, the composition according to methods and protocols described herein Tu Benwen inhibits the growth, colonization, and/or reduces the viability of microorganisms that cause skin conditions, such as the lipophilic yeast Malassezia (Malassezia). Background The human scalp is characterized by a generally high density of terminal hair growth, with many sebaceous glands and microorganisms. The environment helps to establish a specific microenvironment that has an impact on the development of skin pathological conditions including, for example, seborrheic dermatitis and dandruff, psoriasis, atopic dermatitis, hair loss, and scalp aging. Seborrheic dermatitis is a common chronic inflammatory skin condition affecting the scalp and is characterized by erythema and oily scales (squamous rash). The non-inflammatory form of the condition affects approximately 50% of the world population (symptoms are scalp dryness and flaking) and is commonly referred to as dandruff. The dandruff cycle begins with an imbalance of intrinsic factors including host immunity, skin microbiome, sebaceous gland activity, and/or epidermal barrier damage. One or more of these conditions may create favorable conditions that result in malassezia infection. Malassezia species are lipophilic yeasts that account for more than 80% of the fungal population found on human skin. Malassezia furfur is a major species responsible for dandruff and related symptoms and challenges. Other species include malassezia dermatitis (m. dermatis), ma Mala chromogenes (m.equi), malassezia globosa (m.globosa), malassezia japan (m.japonica), malassezia dulcis (m. obtusa), malassezia ovale (m. ovalis) (also known as malassezia ovale (Pityrosporum ovale)), malassezia pachyrhizi (m. PACHYDERMATIS), malassezia restrictus (m. restricta), malassezia molitor Phil (m. slooffiae), malassezia axillaris (m. sympodialis), or combinations thereof. Once an infection is established, seborrheic dermatitis begins to cause an impaired epidermal barrier, increased sebum secretion, further malassezia colonization (and metabolite secretion), which ultimately leads to an amplified inflammatory response. This results in long-term, sometimes chronic, degradation of scalp health and aesthetics. Other conditions such as psoriasis, atopic dermatitis and accelerated scalp aging are also associated with skin damage, oxidative stress, microbial infection, microbiome imbalance and immune response mechanisms. Current market solutions involve the use of irritating and non-selective active chemicals such as coal tar, zinc pyrithione, selenium sulphide, salicylic acid or narrow spectrum antifungal agents, whose activity decreases over time. One limitation of these traditional chemicals is that while such solutions have been shown to be effective against fungal infections and/or for aesthetic purposes by exfoliating scalp plaques, such chemicals have not provided an integral, sustainable, natural solution to the dandruff cycle. Thus, there is a continuing need for new compositions, as well as new methods and treatment regimens, that promote the maintenance of healthy scalp. More particularly, there is a need for compositions and methods for treating and/or preventing dandruff circulation, and in particular for inhibiting or preventing the growth, colonization, and/or reducing the viability of the lipophilic yeast malassezia. There has also recently been a trend towards formulating products using ingredients based on renewable raw materials. Such ingredients are considered "green" or "natural" in that the ingredients are derived from renewable and/or sustainable sources. Thus, the components are more environmentally friendly than components derived from fossil fuels or other non-renewable resources. A component having a high bio-renewable carbon index (BCI), such as greater than 80, indicates that the component contains carbon derived primarily from plant, animal or marine-based sources. Rhamnolipids are interfacial active glycolipids produced by various bacterial species and are examples of "green" components, as they can be prepared by fermentation based on renewable raw materials. It is desirable to provide compositions and methods of use that include active ingredients derived from renewable sources, such as rhamnolipids, which can be used to promote maintenance of healthy scalp. Providing such compositions comprising naturally derived rhamnolipids would meet the sustainability goal of ensuring sustainable consumption through the use of bio-based antibacterial materials. The applicant has de